engleski

Echocardiography parameters before therapy cannot predict cardiotoxicity caused by Trastuzumab

Transthoracic echocardiography (TTE)is the primary diagnostic method for the assessment of cardiotoxicity and immunotherapy is canceled or suspended if the left ventricular ejection fraction (LVEF) is reduced more 15% from baseline or by 10-15% of normal values. In our study, 130 patients (pts) with breast cancer werw treated with trastuzumab adjuvantly for one year. According to guidelines, TTE was performed before the beginning and in 3 months periods during therapy. Pts were divided in two groups: 51 pts with proven cardiotoxicity listed in group A, and 79 pts without sings of cardiotoxicity listed in control group B. Results showed there were no difference in LVEF, end-diastolic size of the LV, wall thickness and diastolic function between two groups at the baseline TTE. In conclusion, our study showed that none of the echocardiography parameters given prior to the trastuzumab therapy was a significant risk factor for the development of cardiotoxicity.

cardiotoxicity ; trastuzumab

nije evidentirano